Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.
about
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Syndecan-4 as a biomarker to p ...... ated with WT1 peptide vaccine.
@en
Syndecan-4 as a biomarker to p ...... ated with WT1 peptide vaccine.
@nl
type
label
Syndecan-4 as a biomarker to p ...... ated with WT1 peptide vaccine.
@en
Syndecan-4 as a biomarker to p ...... ated with WT1 peptide vaccine.
@nl
prefLabel
Syndecan-4 as a biomarker to p ...... ated with WT1 peptide vaccine.
@en
Syndecan-4 as a biomarker to p ...... ated with WT1 peptide vaccine.
@nl
P2093
P2860
P356
P1433
P1476
Syndecan-4 as a biomarker to p ...... eated with WT1 peptide vaccine
@en
P2093
Akihiro Tsuboi
Atsushi Kumanogoh
Fumihiro Fujiki
Haruo Sugiyama
Hiroko Nakajima
Jun Nakata
Naoki Hosen
Naoya Hashimoto
Naoya Tatsumi
Satoshi Takashima
P2860
P356
10.4155/FSOA-2015-0008
P50
P577
2016-10-03T00:00:00Z